PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 26263379-3 2015 This study was designed to test the efficacy of NF-kappaB pathway inhibition in combination with cytotoxic chemotherapy, using docetaxel and ionizing radiation in in vitro models of thyroid cancer. Docetaxel 127-136 nuclear factor kappa B subunit 1 Homo sapiens 48-57 30765600-8 2019 Inhibition of c-Myc and NF-kappaB enhanced the efficacy of docetaxel in tumor xenografts. Docetaxel 59-68 nuclear factor kappa B subunit 1 Homo sapiens 24-33 28485511-0 2017 Combination of Nexrutine and docetaxel suppresses NFkappaB-mediated activation of c-FLIP. Docetaxel 29-38 nuclear factor kappa B subunit 1 Homo sapiens 50-58 23038213-1 2013 BACKGROUND: Previous work showed that the NF-kappaB survival pathway is activated by docetaxel (D) and contributes to D resistance in prostate cancer. Docetaxel 85-94 nuclear factor kappa B subunit 1 Homo sapiens 42-51 24925528-11 2014 Decreases in cell viability, migration, invasion, and survival with a higher sensitivity to docetaxel in vitro and with repressed tumorigenesis in vivo were observed upon SHARPIN silencing, and this was consistent with the results from inhibition of the NFkappaB pathway and its downstream targets. Docetaxel 92-101 nuclear factor kappa B subunit 1 Homo sapiens 254-262 24741455-12 2014 CONCLUSION: We conclude that curcumin may enhance docetaxel"s antitumor activity in ATC cells by interfering with NF-kappaB and COX-2. Docetaxel 50-59 nuclear factor kappa B subunit 1 Homo sapiens 114-123 23138939-0 2013 gamma-tocotrienol enhances the chemosensitivity of human oral cancer cells to docetaxel through the downregulation of the expression of NF-kappaB-regulated anti-apoptotic gene products. Docetaxel 90-99 nuclear factor kappa B subunit 1 Homo sapiens 148-157 23138939-7 2013 Whereas docetaxel stimulated the expression of nuclear factor-kappaB (NF-kappaB) p65 protein in B88 cells, gamma-tocotrienol slightly inhibited the expression of constitutive nuclear p65 protein. Docetaxel 8-17 nuclear factor kappa B subunit 1 Homo sapiens 47-68 23138939-7 2013 Whereas docetaxel stimulated the expression of nuclear factor-kappaB (NF-kappaB) p65 protein in B88 cells, gamma-tocotrienol slightly inhibited the expression of constitutive nuclear p65 protein. Docetaxel 8-17 nuclear factor kappa B subunit 1 Homo sapiens 70-79 23138939-10 2013 In addition, gamma-tocotrienol downregulated the docetaxel-induced expression of NF-kappaB-regulated gene products associated with the inhibition of apoptosis. Docetaxel 49-58 nuclear factor kappa B subunit 1 Homo sapiens 81-90 19414318-1 2009 BACKGROUND: We have reported previously that docetaxel (TXT) induces apoptosis and nuclear factor-kappaB (NF-kappaB) activation, and that blockade of NF-kappaB activation augments TXT-induced apoptosis in human gastric cancer cells. Docetaxel 45-54 nuclear factor kappa B subunit 1 Homo sapiens 83-104 21982118-7 2011 Even though there were lower basal levels of NF-kappaB activity in the PC-3 D12 cells compared to the Parental PC-3, docetaxel induced higher NF-kappaB activity and IkappaB phosphorylation at 3 and 6 hours with only minor changes in the DU-145 cells. Docetaxel 117-126 nuclear factor kappa B subunit 1 Homo sapiens 45-54 21982118-7 2011 Even though there were lower basal levels of NF-kappaB activity in the PC-3 D12 cells compared to the Parental PC-3, docetaxel induced higher NF-kappaB activity and IkappaB phosphorylation at 3 and 6 hours with only minor changes in the DU-145 cells. Docetaxel 117-126 nuclear factor kappa B subunit 1 Homo sapiens 142-151 21982118-8 2011 Inhibition of NF-kappaB with the BAY 11-7082 inhibitor reversed the resistance to Docetaxel. Docetaxel 82-91 nuclear factor kappa B subunit 1 Homo sapiens 14-23 21982118-9 2011 CONCLUSION: This study confirms that multiple mechanisms contribute to Docetaxel resistance and the central transcription factor NF-kappaB plays an immensely important role in determining docetaxel-resistance which may represent an appropriate therapeutic target. Docetaxel 71-80 nuclear factor kappa B subunit 1 Homo sapiens 129-138 21982118-9 2011 CONCLUSION: This study confirms that multiple mechanisms contribute to Docetaxel resistance and the central transcription factor NF-kappaB plays an immensely important role in determining docetaxel-resistance which may represent an appropriate therapeutic target. Docetaxel 188-197 nuclear factor kappa B subunit 1 Homo sapiens 129-138 20056115-0 2010 Combination of ginsenoside Rg3 with docetaxel enhances the susceptibility of prostate cancer cells via inhibition of NF-kappaB. Docetaxel 36-45 nuclear factor kappa B subunit 1 Homo sapiens 117-126 20056115-4 2010 We found that a combination treatment of Rg3 (50 microM) with a conventional agent docetaxel (5 nM) was more effective in the inhibition of prostate cancer cell growth and induction of apoptosis as well as G(0)/G(1) arrest accompanied with the significant inhibition of NF-kappaB activity than those by treatment of Rg3 or docetaxel alone. Docetaxel 83-92 nuclear factor kappa B subunit 1 Homo sapiens 270-279 19850643-0 2010 Nuclear factor-kappa B pathway and response in a phase II trial of bortezomib and docetaxel in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. Docetaxel 82-91 nuclear factor kappa B subunit 1 Homo sapiens 0-22 20618955-5 2010 RESULTS: Our data indicate that the response of prostate cancer (PC) cells to the antimitotic drugs docetaxel (Doc) and 2-methoxyestradiol (2ME2) is dependent on the levels of NF-kappaB activity. Docetaxel 100-109 nuclear factor kappa B subunit 1 Homo sapiens 176-185 20618955-5 2010 RESULTS: Our data indicate that the response of prostate cancer (PC) cells to the antimitotic drugs docetaxel (Doc) and 2-methoxyestradiol (2ME2) is dependent on the levels of NF-kappaB activity. Docetaxel 111-114 nuclear factor kappa B subunit 1 Homo sapiens 176-185 20618955-7 2010 Treatment of LNCaP cells with parthenolide, a pharmacologic inhibitor of NF-kappaB, or introduction of dominant-negative IkappaBalpha, or an shRNA specific for p65, a component of the NF-kappaB heterodimer, blocked apoptosis induced by Doc and 2ME2. Docetaxel 236-239 nuclear factor kappa B subunit 1 Homo sapiens 184-193 20618955-9 2010 However, the combination of Doc or 2ME2 with betulinic acid (BA), a triterpenoid that activates NF-kappaB, stimulated apoptosis in LNCaP and non-apoptotic cell death in DU145 and PC3 cells. Docetaxel 28-31 nuclear factor kappa B subunit 1 Homo sapiens 96-105 20618955-10 2010 Increased sensitivity to cell death mediated by the Doc or 2ME2 + BA combination is likely due to increased NF-kappaB activity. Docetaxel 52-55 nuclear factor kappa B subunit 1 Homo sapiens 108-117 19834284-0 2009 Obovatol enhances docetaxel-induced prostate and colon cancer cell death through inactivation of nuclear transcription factor-kappaB. Docetaxel 18-27 nuclear factor kappa B subunit 1 Homo sapiens 97-132 19531569-5 2009 NF-kappaB activity was completely abrogated in cells treated with a combination of thiacremonone and docetaxel, whereas thiacremonone on its own did not alter NF-kappaB activity. Docetaxel 101-110 nuclear factor kappa B subunit 1 Homo sapiens 0-9 19414318-1 2009 BACKGROUND: We have reported previously that docetaxel (TXT) induces apoptosis and nuclear factor-kappaB (NF-kappaB) activation, and that blockade of NF-kappaB activation augments TXT-induced apoptosis in human gastric cancer cells. Docetaxel 45-54 nuclear factor kappa B subunit 1 Homo sapiens 106-115 19414318-1 2009 BACKGROUND: We have reported previously that docetaxel (TXT) induces apoptosis and nuclear factor-kappaB (NF-kappaB) activation, and that blockade of NF-kappaB activation augments TXT-induced apoptosis in human gastric cancer cells. Docetaxel 45-54 nuclear factor kappa B subunit 1 Homo sapiens 150-159 19414318-1 2009 BACKGROUND: We have reported previously that docetaxel (TXT) induces apoptosis and nuclear factor-kappaB (NF-kappaB) activation, and that blockade of NF-kappaB activation augments TXT-induced apoptosis in human gastric cancer cells. Docetaxel 56-59 nuclear factor kappa B subunit 1 Homo sapiens 83-104 19414318-1 2009 BACKGROUND: We have reported previously that docetaxel (TXT) induces apoptosis and nuclear factor-kappaB (NF-kappaB) activation, and that blockade of NF-kappaB activation augments TXT-induced apoptosis in human gastric cancer cells. Docetaxel 56-59 nuclear factor kappa B subunit 1 Homo sapiens 106-115 19414318-1 2009 BACKGROUND: We have reported previously that docetaxel (TXT) induces apoptosis and nuclear factor-kappaB (NF-kappaB) activation, and that blockade of NF-kappaB activation augments TXT-induced apoptosis in human gastric cancer cells. Docetaxel 56-59 nuclear factor kappa B subunit 1 Homo sapiens 150-159 19414318-1 2009 BACKGROUND: We have reported previously that docetaxel (TXT) induces apoptosis and nuclear factor-kappaB (NF-kappaB) activation, and that blockade of NF-kappaB activation augments TXT-induced apoptosis in human gastric cancer cells. Docetaxel 180-183 nuclear factor kappa B subunit 1 Homo sapiens 150-159 17913854-3 2007 However, little is known regarding the inactivation of Akt/NF-kappaB that leads to chemosensitization of breast cancer cells to chemotherapeutic agents, such as Taxotere. Docetaxel 161-169 nuclear factor kappa B subunit 1 Homo sapiens 59-68 19050703-3 2008 Dexamethasone also attenuated docetaxel-induced NF-kappaB and activator protein-1 transcription and reduced docetaxel-promoted expression/secretion of IL-8 and CXCL1 in PC3 and hBMECs. Docetaxel 30-39 nuclear factor kappa B subunit 1 Homo sapiens 48-57 18426800-6 2008 PIM1 in turn mediates docetaxel-induced activation of NFkappaB transcriptional activity, and PIM1 depends in part on RELA/p65 proteins for its prosurvival effects. Docetaxel 22-31 nuclear factor kappa B subunit 1 Homo sapiens 54-62 18426800-7 2008 The PIM1 kinase plays a critical role in this STAT3 --> PIM1 --> NFkappaB stress response pathway and serves as a target for intervention to enhance the therapeutic effects of cytotoxic drugs such as docetaxel. Docetaxel 206-215 nuclear factor kappa B subunit 1 Homo sapiens 71-79 17913854-8 2007 Moreover, we found that NF-kappaB activity was significantly decreased in cells treated with B-DIM and Taxotere. Docetaxel 103-111 nuclear factor kappa B subunit 1 Homo sapiens 24-33 17913854-9 2007 We also have tested our hypothesis using transfection studies, followed by combination treatment with B-DIM/Taxotere, and found that combination treatment significantly inhibited cell growth and induced apoptosis in MDA-MB-231 breast cancer cells mediated by the inactivation of NF-kappaB, a specific target in vitro and in vivo. Docetaxel 108-116 nuclear factor kappa B subunit 1 Homo sapiens 279-288 17913854-10 2007 These results were also supported by animal experiments, which clearly showed that B-DIM sensitized the breast tumors to Taxotere, which resulted in greater antitumor activity mediated by the inhibition of Akt and NF-kappaB. Docetaxel 121-129 nuclear factor kappa B subunit 1 Homo sapiens 214-223 17913854-11 2007 Collectively, our results clearly suggest that inhibition of Akt/NF-kappaB signaling by B-DIM leads to chemosensitization of breast cancer cells to Taxotere, which may contribute to increased growth inhibition and apoptosis in breast cancer cells. Docetaxel 148-156 nuclear factor kappa B subunit 1 Homo sapiens 65-74 16622259-12 2006 NF-kappaB activation and increased expression of TNF-alpha were associated with increments in docetaxel dose. Docetaxel 94-103 nuclear factor kappa B subunit 1 Homo sapiens 0-9 17638896-8 2007 IL8-S cells expressed 2- to 3-fold higher levels of phospho-EGFR, src, Akt, and nuclear factor kappaB (NF-kappaB) and showed increased survival when treated with docetaxel. Docetaxel 162-171 nuclear factor kappa B subunit 1 Homo sapiens 95-101 17638896-8 2007 IL8-S cells expressed 2- to 3-fold higher levels of phospho-EGFR, src, Akt, and nuclear factor kappaB (NF-kappaB) and showed increased survival when treated with docetaxel. Docetaxel 162-171 nuclear factor kappa B subunit 1 Homo sapiens 103-112 14614027-0 2003 Cyclosporin-A enhances docetaxel-induced apoptosis through inhibition of nuclear factor-kappaB activation in human gastric carcinoma cells. Docetaxel 23-32 nuclear factor kappa B subunit 1 Homo sapiens 73-94 15097869-10 2004 Moreover, the NF-kappaB activity was significantly increased within 2 hours of docetaxel or cisplatin treatment, and the NF-kappaB-inducing activity of these agents was completely abrogated in cells pretreated with genistein. Docetaxel 79-88 nuclear factor kappa B subunit 1 Homo sapiens 14-23 15097869-11 2004 These results clearly suggest that genistein pretreatment, which inactivates NF-kappaB activity, together with other cellular effects of genistein, may contribute to increased cell growth inhibition and apoptosis inducing effects of nontoxic doses of docetaxel and cisplatin, which could be a novel strategy for the treatment of pancreatic cancer. Docetaxel 251-260 nuclear factor kappa B subunit 1 Homo sapiens 77-86 16613577-5 2006 Recently, we found that genistein sensitized cancer cells to apoptosis induced by chemotherapeutic agents including docetaxel, gemcitabine and cisplatin through inactivation of NF-kappaB in multiple cancer cell lines. Docetaxel 116-125 nuclear factor kappa B subunit 1 Homo sapiens 177-186 16061678-9 2005 Moreover, we found that the NF-kappaB activity was significantly increased within 2 hours of cisplatin and docetaxel treatment and that the NF-kappaB inducing activity of these agents was completely abrogated in cells pretreated with genistein. Docetaxel 107-116 nuclear factor kappa B subunit 1 Homo sapiens 28-37 15956258-7 2005 In addition, nuclear NF-kappaB levels were lower in residual tumors and lung metastasis of animals treated with parthenolide, docetaxel, or both. Docetaxel 126-135 nuclear factor kappa B subunit 1 Homo sapiens 21-30 12687011-0 2003 PSK-mediated NF-kappaB inhibition augments docetaxel-induced apoptosis in human pancreatic cancer cells NOR-P1. Docetaxel 43-52 nuclear factor kappa B subunit 1 Homo sapiens 13-22 12687011-6 2003 Furthermore, PSK inhibited docetaxel-induced nuclear factor kappa B (NF-kappaB) activation. Docetaxel 27-36 nuclear factor kappa B subunit 1 Homo sapiens 45-67 12687011-6 2003 Furthermore, PSK inhibited docetaxel-induced nuclear factor kappa B (NF-kappaB) activation. Docetaxel 27-36 nuclear factor kappa B subunit 1 Homo sapiens 69-78 12687011-7 2003 Moreover, the expression of cellular inhibitor of apoptosis protein (cIAP-1), which is transcriptionally regulated by NF-kappaB and functions as an antiapoptotic molecule through interrupting the caspase pathway, was also inhibited by treatment with PSK plus docetaxel. Docetaxel 259-268 nuclear factor kappa B subunit 1 Homo sapiens 118-127 12687011-9 2003 In addition, treatment by transfection of NF-kappaB decoy oligodeoxynucleotides (ODNs), but not scramble ones, inhibited the expression of cIAP-1 in NOR-P1 cells and induced a significant increase in docetaxel-induced apoptosis. Docetaxel 200-209 nuclear factor kappa B subunit 1 Homo sapiens 42-51 12687011-10 2003 Our data indicate that PSK suppresses the docetaxel-induced NF-kappaB activation pathway. Docetaxel 42-51 nuclear factor kappa B subunit 1 Homo sapiens 60-69